Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | CHIEF FINANCIAL OFFICER | March 11, 2024 | March 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date March 11, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,465 |
Ending reported balance
After 2024-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-11 · Exercise / conversion · Acquired 4,908 · Balance 99,377 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2024-03-11 · Tax withholding · Disposed 1,912 · Balance 97,465 F2: Represents the number of shares withheld by and surrendered to the Issuer on March 11, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 44,182 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Exercise / conversion · Disposed 4,908 · Balance 44,182 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on March 11, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2022 Filed Aug 25, 2022 22:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 3,500 | $13.45 | $47,075.00 |
DisclosureSEC source: 0001209191-22-047576 · doc4.xml · nonDerivative · entry 1 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,563 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:33 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,752 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046946 · doc4.xml · derivative · entry 3 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,954 Underlying: Common Stock · 1,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:33 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 683 | $14.06 | $9,602.98 |
DisclosureSEC source: 0001209191-22-046946 · doc4.xml · nonDerivative · entry 2 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,063 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:33 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046946 · doc4.xml · nonDerivative · entry 1 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | SaleCommon Stock | 3,500 | $12.80 | $44,800.00 |
DisclosureSEC source: 0001209191-22-044309 · doc4.xml · nonDerivative · entry 1 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,994 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.62 to $12.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 1,071 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,336 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031164 · doc4.xml · derivative · entry 3 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,706 Underlying: Common Stock · 2,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 910 | $9.65 | $8,781.50 |
DisclosureSEC source: 0001209191-22-031164 · doc4.xml · nonDerivative · entry 2 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,423 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:12 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,336 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031164 · doc4.xml · nonDerivative · entry 1 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 28,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014992 · doc4.xml · derivative · entry 2 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,042 Underlying: Common Stock · 28,042 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:54 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 42,310 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001209191-22-014992 · doc4.xml · derivative · entry 1 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,310 Underlying: Common Stock · 42,310 shares Expires 2032-02-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026. Read SEC document |
| July 22, 2021 Filed Jul 27, 2021 01:49 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048268 · doc4.xml · derivative · entry 1 Jeanmonod Patrik · CIK 0001873085 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-07-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.